Persbericht: Programma bekend van gebruikersevent GiLab Commit 2019
Amsterdam — 30 augustus 2019 — GitLab, het DevOps platform,... Lees verder →
- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of ...
Lees verder- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata ...
Lees verderROTTERDAM, Nederland, 18 juni 2019 /PRNewswire/ -- Terwijl leiders samenkomen op de International Ministerial Conference over antimicrobiële resistentie (AMR), roepen ...
Lees verderLONDON, August 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet ...
Lees verderTAIPEI, Taiwan, July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed a Phase 1 multiple ...
Lees verderLONDON and CARLSBAD, California, January 24, 2018 /PRNewswire/ -- - First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of ...
Lees verderLONDON, December 29, 2017 /PRNewswire/ -- GW Pharmaceuticals plc , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from ...
Lees verderHighlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-025, a Selective MMP-12 Inhibitor. TAIPEI, Taiwan, Dec. 4, 2017 /PRNewswire/ -- Foresee ...
Lees verderTAIPEI, Taiwan, July 31, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the appointment of Dr. Lawrence Gan to the position of ...
Lees verderLAUSANNE, Switzerland and ATLANTA, June 30, 2017 /PRNewswire/ -- Triptodur(TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse ...
Lees verder